Loading stock…

Shanghai Pharmaceuticals Holding Co., Ltd (601607) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Shanghai Pharmaceuticals Holding Co., Ltd

601607Market cap $8.14BPrice $2.5

Country🇨🇳China

SectorHealthcare

IndustryHealthcare Services

Distributes and manufactures pharmaceuticals across China, running one of the country's largest drug distribution networks. It moves medicines from factories to hospitals and pharmacies nationwide, touching nearly every prescription filled in Shanghai and beyond.

In Bastion Portfolios?

52W Return-1%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+6%5

Rev CAGR (5y)+8%6

Earnings Forecast

EPS Growth Y+1+15%7

EPS Growth Y+2+8%6

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin3%2

Net Income Margin2%2

Free Cash Flow Margin3%3

Debt

Net Debt/EBITDA1.16

Efficiency

ROE6%3

ROA3%4

Earnings Stability44

GEAR+STRONG77

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)89

P/E Ratio (Forward 3y)89

P/BV0.710

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd710

Yield

Free Cash Flow Yield13.3%10

Dividend Yieldna–

Momentum

Short term

1 month return+1%8

3 month return+5%8

YTD return-5%4

Mid term

Price vs 52wHigh93%9

1 year return-7%4

Long term

3 year return-2%3

5 year return-3%3

Risk Shield

Price Risk

Beta0.010

Volatility15%10

Free Cash Flow

Free Cash Flow Margin3%3

Free Cash Flow Yield13.3%10

Quality

ROCE9%5

Earnings Stability44

Net Debt/EBITDA1.16

02Growth

Is it actually growing, and how fast?

601607Shanghai Pharmaceuticals Holding Co.

Revenue FY25$40.6B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+8%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+15%7

EPS growth, FY27E+8%6

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 8%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

601607Shanghai Pharmaceuticals Holding Co.

Total return Current9.2%

Price return Current−11.5%

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+5%8

YTD return-5%4

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return-7%4

3-year return-2%3

5-year return-3%3

MOMENTUM ASSESSMENT

STRENGTHS

It's down 7% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%) and over three months (+5%).

WATCH

Returns sit at the market level so far this year (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-1.8% over three years and -3.2% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Shanghai Pharmaceuticals Holding Co., Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

601607Shanghai Pharmaceuticals Holding Co.

Revenue FY25$40.6B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+8%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+15%7

EPS growth, FY27E+8%6

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 8%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

601607Shanghai Pharmaceuticals Holding Co.

Total return Current9.2%

Price return Current−11.5%

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+5%8

YTD return-5%4

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return-7%4

3-year return-2%3

5-year return-3%3

MOMENTUM ASSESSMENT

STRENGTHS

It's down 7% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%) and over three months (+5%).

WATCH

Returns sit at the market level so far this year (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-1.8% over three years and -3.2% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Shanghai Pharmaceuticals Holding Co., Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community